Ozempic vs Wegovy: What's the Difference?

Ozempic and Wegovy show up in the same conversations so often that a lot of people assume they're competing drugs. They're not. They are the same active ingredient, sold under two names for two different approved uses, at two different maximum doses. Here's exactly what that means in practice.

Same Drug, Different Approved Use

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Ozempic was FDA-approved in 2017 to treat type 2 diabetes and to reduce cardiovascular risk in people with heart disease. Wegovy was approved in 2021 specifically for chronic weight management in adults with obesity, or overweight with a weight-related condition.

Because Ozempic isn't approved specifically for weight loss, some doctors prescribe it off-label for that purpose. That's legal, but it means insurance coverage, dosing guidance, and clinical trial data specific to weight loss all point toward Wegovy as the on-label choice for that use.

Dose Differences

The two drugs are dosed differently, which is part of why Wegovy tends to produce more weight loss on average.

A nurse practitioner and weight-loss clinic co-owner told Drugwatch that the two are essentially the same drug at different doses, with Wegovy's higher ceiling being the main pharmacological difference. That higher dose also comes with a somewhat higher rate of nausea, vomiting and diarrhea in clinical comparisons.

Cost and Coverage

Because they carry different FDA-approved indications, insurance treats them very differently. Ozempic, as a diabetes drug, is broadly covered by commercial insurance, Medicare Part D and Medicaid, usually with modest copays once approved. Wegovy, as a weight-management drug, has historically faced patchier coverage, though this has expanded substantially, with most major commercial insurers now covering it for patients who meet BMI criteria, and Medicare coverage for GLP-1 weight-loss drugs beginning in mid-2026 for qualifying patients under a bridge program.

List prices for both have moved in 2026 following negotiated federal pricing agreements, and manufacturer savings cards can bring the out-of-pocket cost for eligible commercially insured patients down substantially. Prices and coverage terms change frequently, so confirm current numbers with your pharmacy or insurer rather than relying on any single published figure.

Coverage and pricing for Ozempic and Wegovy differ because of their different FDA-approved uses.

Can You Switch Between Them?

Since they contain the same active ingredient, switching between Ozempic and Wegovy under medical supervision is possible and sometimes done for insurance or dosing reasons. It isn't something to do on your own, though, because dose titration schedules differ and your prescriber needs to manage the transition based on your specific health goals.

If you're weighing this drug family against the tirzepatide-based alternatives, see Mounjaro vs Zepbound for the equivalent comparison on that side, and GLP-1 drugs explained for how the two molecule families compare to each other.

Side Effects: How Similar Are They?

Because Ozempic and Wegovy share an active ingredient, their side-effect profiles overlap heavily: nausea, vomiting, diarrhea, and constipation are common to both, especially during dose increases. Wegovy's higher maximum dose does appear to shift the balance slightly toward more frequent gastrointestinal side effects at the top of its range compared to Ozempic's lower ceiling, simply because a higher dose means a stronger effect on gut motility.

Both carry the same boxed warning regarding thyroid C-cell tumors observed in rodent studies, and both require the same caution around personal or family history of certain thyroid cancers or multiple endocrine neoplasia syndrome type 2. If you're managing side effects on either drug, our dedicated guides to GLP-1 nausea and GLP-1 constipation apply equally to both.

Availability and Shortages

Both drugs have experienced periods of supply shortage since demand accelerated sharply from 2022 onward, particularly at lower starting doses as manufacturers prioritized production of higher maintenance doses. The FDA maintains a public drug shortage database where you can check the current status of specific doses for both Ozempic and Wegovy, since availability can vary by dose strength and by pharmacy.

If your regular pharmacy is out of stock at your prescribed dose, ask your prescriber about alternative doses, other pharmacies, or manufacturer-run locator tools, rather than switching to a compounded alternative or an unfamiliar online source without your prescriber's involvement.

What the Clinical Trials Actually Measured

The weight-loss figures often quoted for these drugs come from specific, named trial programs, and it's worth knowing their names since you'll see them referenced across prescribing information and independent research. Ozempic's diabetes and cardiovascular data comes largely from the SUSTAIN trial series, while Wegovy's weight-management approval rested on the STEP (Semaglutide Treatment Effect in People with obesity) trial program, which enrolled thousands of adults with obesity or overweight, most without diabetes, over roughly 68 weeks.

In the STEP 1 trial specifically, participants on 2.4 mg semaglutide weekly lost an average of about 15% of body weight over 68 weeks, compared to roughly 2.4% in the placebo group, which also received counseling on diet and exercise. That gap, not the raw percentage alone, is what regulators and clinicians weigh most heavily when evaluating how much of the effect comes from the drug itself.

A Note on Compounded Semaglutide

During the FDA's official drug shortage listing for semaglutide, compounding pharmacies were legally permitted to produce compounded versions of the drug, and many telehealth companies built entire business models around cheaper compounded alternatives. Once FDA shortages are formally resolved, compounded versions of an FDA-approved drug generally must stop unless they meet specific individual patient-need criteria under federal law.

Compounded semaglutide is not FDA-approved as a finished drug product, meaning it hasn't undergone the same manufacturing oversight, and its safety and effectiveness haven't been independently verified in the same way as Ozempic or Wegovy. If cost is the barrier, manufacturer savings programs and expanding insurance coverage are generally the safer route to pursue before considering a compounded alternative, and this is a conversation worth having directly with a licensed prescriber.

How to Decide Which One Is Right for You

This isn't really a choice most people make freely, since it's largely determined by your diagnosis and what your insurance will cover. That said, a few practical questions are worth raising with your prescriber.

1. Do you have type 2 diabetes, or is weight management the primary goal? This alone often determines which brand your insurance will approve.
2. What does your insurance actually cover? Ask your pharmacy to run both before assuming either is unaffordable.
3. Are you comfortable with a higher maximum dose if it's medically appropriate? Wegovy's higher ceiling means somewhat more GI side effects for somewhat more weight loss, on average.
4. Would an oral option fit your life better than a weekly injection? Both semaglutide-based oral tablets, see oral GLP-1 drugs explained, are now available.

Frequently Asked Questions

Is Wegovy stronger than Ozempic?

Wegovy is approved at a higher maximum dose (2.4 mg weekly, or 7.2 mg for Wegovy HD) than Ozempic (2 mg weekly), which is one reason it tends to produce more weight loss on average. They contain the same active ingredient, semaglutide.

Can I get Ozempic for weight loss instead of Wegovy?

Some doctors prescribe Ozempic off-label for weight loss, but Wegovy is the drug specifically FDA-approved and dosed for that purpose, and insurance coverage typically reflects that distinction.

Why do Ozempic and Wegovy cost different amounts?

Because they carry different FDA-approved indications, insurers cover them differently, and manufacturers set separate list prices and savings programs for each brand, even though the drug itself is the same molecule.

Is it safe to switch from Ozempic to Wegovy?

It can be done under medical supervision since they share an active ingredient, but the dose titration and reason for switching should be managed by your prescriber rather than done independently.

Sources and References

1. Drugs.com — Difference Between Ozempic and Wegovy
2. Medical News Today — Ozempic vs. Wegovy: What's the difference?, 2026
3. Drugwatch — Wegovy vs. Ozempic: Important Differences To Consider
4. FDA — Wegovy (semaglutide) prescribing information